Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: An actual challenge

Carlo G. Tocchetti; Gianluca Ragone; Carmela Coppola; Domenica Rea; Giovanna Piscopo; Stefania Scala; Claudia De Lorenzo; Rosario V. Iaffaioli; Claudio Arra; Nicola Maurea

doi:10.1093/eurjhf/hfr165

Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: An actual challenge

Carlo G. Tocchetti, Gianluca Ragone, Carmela Coppola, Domenica Rea, Giovanna Piscopo, Stefania Scala, Claudia De Lorenzo, Rosario V. Iaffaioli, Claudio Arra, Nicola Maurea

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

The antibody trastuzumab, targeted to inhibit the signalling of ErbB2, a tyrosine kinase receptor overexpressed in 2030 of breast cancers, improves the prognosis in women affected by this tumour, but produces cardiotoxicity, since ErbB2 is also involved in myocardial homeostasis. In this review, we discuss the pathophysiology of trastuzumab cardiomyopathy and the complex interplay between ErbB2 inhibition and anthracyclines, and we focus on the actual challenges of detecting, monitoring, and managing trastuzumab cardiotoxicity: the research of new, sensitive markers of early trastuzumab toxicity, before the ejection fraction is reduced, is an active field of research.

Original language	English
Pages (from-to)	130-137
Number of pages	8
Journal	European Journal of Heart Failure
Volume	14
Issue number	2
DOIs	https://doi.org/10.1093/eurjhf/hfr165
Publication status	Published - Feb 2012

Keywords

Anthracyclines
Biomarkers
Ejection fraction
ErbB2
New echocardiographic techniques
Trastuzumab cardiomyopathy

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1093/eurjhf/hfr165

Cite this

@article{ad7fc92d6086480e8b01a62d2a2cf729,

title = "Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: An actual challenge",

abstract = "The antibody trastuzumab, targeted to inhibit the signalling of ErbB2, a tyrosine kinase receptor overexpressed in 2030 of breast cancers, improves the prognosis in women affected by this tumour, but produces cardiotoxicity, since ErbB2 is also involved in myocardial homeostasis. In this review, we discuss the pathophysiology of trastuzumab cardiomyopathy and the complex interplay between ErbB2 inhibition and anthracyclines, and we focus on the actual challenges of detecting, monitoring, and managing trastuzumab cardiotoxicity: the research of new, sensitive markers of early trastuzumab toxicity, before the ejection fraction is reduced, is an active field of research.",

keywords = "Anthracyclines, Biomarkers, Ejection fraction, ErbB2, New echocardiographic techniques, Trastuzumab cardiomyopathy",

author = "Tocchetti, {Carlo G.} and Gianluca Ragone and Carmela Coppola and Domenica Rea and Giovanna Piscopo and Stefania Scala and {De Lorenzo}, Claudia and Iaffaioli, {Rosario V.} and Claudio Arra and Nicola Maurea",

year = "2012",

month = feb,

doi = "10.1093/eurjhf/hfr165",

language = "English",

volume = "14",

pages = "130--137",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "John Wiley & Sons, Ltd",

number = "2",

}

TY - JOUR

T1 - Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction

T2 - An actual challenge

AU - Tocchetti, Carlo G.

AU - Ragone, Gianluca

AU - Coppola, Carmela

AU - Rea, Domenica

AU - Piscopo, Giovanna

AU - Scala, Stefania

AU - De Lorenzo, Claudia

AU - Iaffaioli, Rosario V.

AU - Arra, Claudio

AU - Maurea, Nicola

PY - 2012/2

Y1 - 2012/2

N2 - The antibody trastuzumab, targeted to inhibit the signalling of ErbB2, a tyrosine kinase receptor overexpressed in 2030 of breast cancers, improves the prognosis in women affected by this tumour, but produces cardiotoxicity, since ErbB2 is also involved in myocardial homeostasis. In this review, we discuss the pathophysiology of trastuzumab cardiomyopathy and the complex interplay between ErbB2 inhibition and anthracyclines, and we focus on the actual challenges of detecting, monitoring, and managing trastuzumab cardiotoxicity: the research of new, sensitive markers of early trastuzumab toxicity, before the ejection fraction is reduced, is an active field of research.

AB - The antibody trastuzumab, targeted to inhibit the signalling of ErbB2, a tyrosine kinase receptor overexpressed in 2030 of breast cancers, improves the prognosis in women affected by this tumour, but produces cardiotoxicity, since ErbB2 is also involved in myocardial homeostasis. In this review, we discuss the pathophysiology of trastuzumab cardiomyopathy and the complex interplay between ErbB2 inhibition and anthracyclines, and we focus on the actual challenges of detecting, monitoring, and managing trastuzumab cardiotoxicity: the research of new, sensitive markers of early trastuzumab toxicity, before the ejection fraction is reduced, is an active field of research.

KW - Anthracyclines

KW - Biomarkers

KW - Ejection fraction

KW - ErbB2

KW - New echocardiographic techniques

KW - Trastuzumab cardiomyopathy

UR - http://www.scopus.com/inward/record.url?scp=84856166090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856166090&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfr165

DO - 10.1093/eurjhf/hfr165

M3 - Article

C2 - 22219501

AN - SCOPUS:84856166090

SN - 1388-9842

VL - 14

SP - 130

EP - 137

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 2

ER -

Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: An actual challenge

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this